The shadow of generic rivalry has long loomed over copyright’s blockbuster drug, Viagra, triggering questions about the outlook of related drug portfolios. While initial times saw significant returns, the exclusivity expiration has allowed the path for discounted substitutes, potentially lowering earnings and posing a real danger for shareholders